Thienopyridines and other ADP-receptor antagonists

Handbook of Experimental Pharmacology

Volumn 210, Issue , 2012, Pages 165-198

  Bernlochner, Isabell ^a   Sibbing, Dirk ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Non thienopyridines; P2Y12 receptor inhibition; Platelet function testing; Platelet reactivity; Thienopyridines

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ARC 69931MX; ARYLDIALKYLPHOSPHATASE 1; CANGRELOR; CLOPIDOGREL; CYTOCHROME P450; CYTOCHROME P450 2C19; ELINOGREL; FIBRINOGEN RECEPTOR; OMEPRAZOLE; PANTOPRAZOLE; PHENPROCOUMON; PLACEBO; PRASUGREL; PURINERGIC P2Y12 RECEPTOR; THIENOPYRIDINE DERIVATIVE; TICAGRELOR; TICLOPIDINE; UNCLASSIFIED DRUG; WARFARIN; ADENOSINE; ADENOSINE PHOSPHATE; DRUG DERIVATIVE; PIPERAZINE DERIVATIVE; PURINERGIC P2Y RECEPTOR ANTAGONIST; QUINAZOLINONE DERIVATIVE; SULFONAMIDE; THIOPHENE DERIVATIVE;

ACUTE CORONARY SYNDROME; APLASTIC ANEMIA; ARTICLE; BLEEDING; BRADYCARDIA; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; CORONARY ARTERY DISEASE; CREATININE BLOOD LEVEL; DOSE RESPONSE; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG DEGRADATION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; ENZYME INHIBITION; GASTROINTESTINAL DISEASE; GENE FREQUENCY; GENETIC VARIABILITY; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HIGH RISK PATIENT; HUMAN; ISCHEMIA; LOADING DRUG DOSE; MAINTENANCE DRUG DOSE; MONOTHERAPY; NEUTROPENIA; OUTCOME ASSESSMENT; PATHOGENESIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; SIDE EFFECT; SINGLE DRUG DOSE; SINGLE NUCLEOTIDE POLYMORPHISM; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT THROMBOSIS; THROMBOCYTE AGGREGATION INHIBITION; THROMBOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; URIC ACID BLOOD LEVEL; ANIMAL; REVIEW;

ADENOSINE; ADENOSINE MONOPHOSPHATE; ANIMALS; HUMANS; PIPERAZINES; PURINERGIC P2Y RECEPTOR ANTAGONISTS; QUINAZOLINONES; SULFONAMIDES; THIENOPYRIDINES; THIOPHENES; TICLOPIDINE;

EID: 84867163755     PISSN: 01712004     EISSN: 18650325     Source Type: Book Series    
DOI: 10.1007/978-3-642-29423-5_7     Document Type: Article

References (172)

1. Anderson JL, Adams CD, Antman EM et al (2007) ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation 116:e148-e304
2. Barragan P, Bouvier JL, Roquebert PO et al (2003) Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation. Catheter Cardiovasc Interv 59:295-302
3. Bassand JP, Hamm CW, Ardissino D et al (2007) Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J 28:1598-1660
4. Beinema M, Brouwers JR, Schalekamp T et al (2008) Pharmacogenetic differences between warfarin, acenocoumarol and phenprocoumon. Thromb Haemost 100:1052-1057
5. Berger PB, Bell MR, Rihal CS et al (1999) Clopidogrel versus ticlopidine after intracoronary stent placement. J Am Coll Cardiol 34:1891-1894
6. Berger JS, Roe MT, Gibson CM et al (2009) Safety and feasibility of adjunctive antiplatelet therapy with intravenous elinogrel, a direct-acting and reversible P2Y12 ADP-receptor antagonist, before primary percutaneous intervention in patients with ST-elevation myocardial infarction: the Early Rapid ReversAl of platelet thromboSis with intravenous Elinogrel before PCI to optimize reperfusion in acute Myocardial Infarction (ERASE MI) pilot trial. Am Heart J 158(998-1004):e1001
7. Bernlochner I, Steinhubl S, Braun S et al (2010) Association between inflammatory biomarkers and platelet aggregation in patients under chronic clopidogrel treatment. Thromb Haemost 104:1193-1200
8. Bertrand ME, Rupprecht HJ, Urban P et al (2000) Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation 102:624-629
9. Bhatt DL, Lincoff AM, Gibson CM et al (2009) Intravenous platelet blockade with cangrelor during PCI. N Engl J Med 361:2330-2341
10. Bhatt DL, Cryer BL, Contant CF et al (2010) Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med 363:1909-1917
11. Björkman JA KI, van Giezen JJJ. (2007) AZD6140 inhibits adenosine uptake into erythrocytes and enhances coronary blood flow after local ischemia or intracoronary adenosine infusion. Circulation 116:II-28 (Abstract 245)
12. Blindt R, Stellbrink K, de Taeye A et al (2007) The significance of vasodilator-stimulated phosphoprotein for risk stratification of stent thrombosis. Thromb Haemost 98:1329-1334
13. Bonello L, Paganelli F, Arpin-Bornet M et al (2007) Vasodilator- stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events. J Thromb Haemost 5:1630-1636
14. Bonello L, Camoin-Jau L, Arques S et al (2008) Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study. J Am Coll Cardiol 51:1404-1411
15. Bonello L, Camoin-Jau L, Armero S et al (2009) Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis. Am J Cardiol 103:5-10
16. Bonello L, Tantry US, Marcucci R et al (2010) Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 56:919-933
17. Bonello L, Pansieri M, Mancini J et al (2011) High on-treatment platelet reactivity after prasugrel loading dose and cardiovascular events after percutaneous coronary intervention in acute coronary syndromes. J Am Coll Cardiol 58:467-473
18. Bouman HJ, Schomig E, van Werkum JW et al (2011) Paraoxonase-1 is a major determinant of clopidogrel efficacy. Nat Med 17:110-116
19. Brandt JT, Close SL, Iturria SJ et al (2007a) Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost 5:2429-2436
20. Brandt JT, Payne CD, Wiviott SD et al (2007b) A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. Am Heart J 153(1):66.e9-66.e16
21. Breet NJ, van Werkum JW, Bouman HJ et al (2010) Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA 303:754-762
22. Buonamici P, Marcucci R, Migliorini A et al (2007) Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol 49:2312-2317
23. Campo G, Parrinello G, Ferraresi P et al (2011) Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome. J Am Coll Cardiol 57:2474-2483
24. Cannon CP, Husted S, Harrington RA et al (2007) Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. J Am Coll Cardiol 50:1844-1851
25. Cattaneo M (2010) New P2Y(12) inhibitors. Circulation 121:171-179
26. Chen L, Bracey AW, Radovancevic R et al (2004) Clopidogrel and bleeding in patients undergoing elective coronary artery bypass grafting. J Thorac Cardiovasc Surg 128:425-431
27. Collet JP, Hulot JS, Pena A et al (2009) Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 373:309-317
28. Committee CS (1996) A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 348:1329-1339
29. Cuisset T, Frere C, Quilici J et al (2006) High post-treatment platelet reactivity identified lowresponders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome. J Thromb Haemost 4:542-549
30. Cuisset T, Cayla G, Frere C et al (2009a) Predictive value of post-treatment platelet reactivity for occurrence of post-discharge bleeding after non-ST elevation acute coronary syndrome. Shifting from antiplatelet resistance to bleeding risk assessment? EuroIntervention 5:325-329
31. Cuisset T, Frere C, Quilici J et al (2009b) Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose the PACA (Proton Pump Inhibitors And Clopidogrel Association) prospective randomized study. J Am Coll Cardiol 54:1149-1153
32. Dalvie DK, O'Connell TN (2004) Characterization of novel dihydrothienopyridinium and thienopyridinium metabolites of ticlopidine in vitro: role of peroxidases, cytochromes p450, and monoamine oxidases. Drug Metab Dispos 32:49-57
33. Davi G, Patrono C (2007) Platelet activation and atherothrombosis. N Engl J Med 357:2482-2494
34. Dorsam RT, Kunapuli SP (2004) Central role of the P2Y12 receptor in platelet activation. J Clin Invest 113:340-345
35. Dovlatova NL, Jakubowski JA, Sugidachi A et al (2008) The reversible P2Y antagonist cangrelor influences the ability of the active metabolites of clopidogrel and prasugrel to produce irreversible inhibition of platelet function. J Thromb Haemost 6:1153-1159
36. Elias M, Reichman N, Flatau E (1993) Bone marrow aplasia associated with ticlopidine therapy. Am J Hematol 44:289-290
37. Eshtehardi P, Windecker S, Cook S et al (2010) Dual low response to acetylsalicylic acid and clopidogrel is associated with myonecrosis and stent thrombosis after coronary stent implantation. Am Heart J 159:891-898 e891
38. Farid NA, Kurihara A, Wrighton SA (2010) Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans. J Clin Pharmacol 50:126-142
39. Ferreiro JL, Ueno M, Angiolillo DJ (2009) Cangrelor: a review on its mechanism of action and clinical development. Expert Rev Cardiovasc Ther 7:1195-1201
40. Fontana P, James R, Barazer I et al (2011) Relationship between paraoxonase-1 activity, its Q192R genetic variant and clopidogrel responsiveness in the ADRIE study. J Thromb Haemost 9:1664-1666
41. Frere C, Cuisset T, Quilici J et al (2007) ADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non-ST elevation acute coronary syndrome. Thromb Haemost 98:838-843
42. Gachet C (2006) Regulation of platelet functions by P2 receptors. Annu Rev Pharmacol Toxicol 46:277-300
43. Gaglia MA Jr, Waksman R (2011) Overview of the 2010 Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee meeting regarding ticagrelor. Circulation 123:451-456
44. Geiger J, Brich J, Honig-Liedl P et al (1999) Specific impairment of human platelet P2Y(AC) ADP receptor-mediated signaling by the antiplatelet drug clopidogrel. Arterioscler Thromb Vasc Biol 19:2007-2011
45. Geisler T, Langer H, Wydymus M et al (2006) Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. Eur Heart J 27:2420-2425
46. Geisler T, Anders N, Paterok M et al (2007) Platelet response to clopidogrel is attenuated in diabetic patients undergoing coronary stent implantation. Diabetes Care 30:372-374
47. Geisler T, Grass D, Bigalke B et al (2008) The Residual Platelet Aggregation after Deployment of Intracoronary Stent (PREDICT) score. J Thromb Haemost 6:54-61
48. Geisler T, Zurn C, Simonenko R et al (2010) Early but not late stent thrombosis is influenced by residual platelet aggregation in patients undergoing coronary interventions. Eur Heart J 31:59-66
49. Gilard M, Arnaud B, Cornily JC et al (2008) Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol 51:256-260
50. Giusti B, Gori AM, Marcucci R et al (2007) Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients. Pharmacogenet Genomics 17:1057-1064
51. Giusti B, Gori AM, Marcucci R et al (2009) Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis. Am J Cardiol 103:806-811
52. Gorchakova O, von Beckerath N, Gawaz M et al (2004) Antiplatelet effects of a 600 mg loading dose of clopidogrel are not attenuated in patients receiving atorvastatin or simvastatin for at least 4 weeks prior to coronary artery stenting. Eur Heart J 25:1898-1902
53. Gori AM, Marcucci R, Migliorini A et al (2008) Incidence and clinical impact of dual nonresponsiveness to aspirin and clopidogrel in patients with drug-eluting stents. J Am Coll Cardiol 52:734-739
54. Greenbaum AB, Grines CL, Bittl JA et al (2006) Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial. Am Heart J 151:689 e681-689 e610
55. Gremmel T, Steiner S, Seidinger D et al (2010) Calcium-channel blockers decrease clopidogrelmediated platelet inhibition. Heart 96:186-189
56. Gurbel PA, Bliden KP, Hiatt BL et al (2003) Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 107:2908-2913
57. Gurbel PA, Bliden KP, Guyer K et al (2005a) Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study. J Am Coll Cardiol 46:1820-1826
58. Gurbel PA, Bliden KP, SamaraWet al (2005b) Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study. J Am Coll Cardiol 46:1827-1832
59. Gurbel PA, Antonino MJ, Bliden KP et al (2008) Platelet reactivity to adenosine diphosphate and long-term ischemic event occurrence following percutaneous coronary intervention: a potential antiplatelet therapeutic target. Platelets 19:595-604
60. Gurbel PA, Bliden KP, Butler K et al (2009) Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation 120:2577-2585
61. Gurbel PA, Bliden KP, Butler K et al (2010a) Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study. Circulation 121:1188-1199
62. Gurbel PA, Bliden KP, Antonino MJ et al (2010b) The effect of elinogrel on high platelet reactivity during dual antiplatelet therapy and the relation to CYP2C19*2 genotype: first experience in patients. J Thromb Haemost 8:43-53
63. Hamm CW, Bassand JP, Agewall S et al (2011) ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 32:2999-3054
64. Harmsze AM, Robijns K, van Werkum JW et al (2010) The use of amlodipine, but not of P-glycoprotein inhibiting calcium channel blockers is associated with clopidogrel poorresponse. Thromb Haemost 103:920-925
65. Harrington RA, Stone GW, McNulty S et al (2009) Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med 361:2318-2329
66. Ho PM, Maddox TM, Wang L et al (2009) Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 301:937-944
67. Hochholzer W, Trenk D, Bestehorn HP et al (2006) Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol 48:1742-1750
68. Hochholzer W, Trenk D, Fromm MF et al (2010) Impact of cytochrome P450 2C19 loss-offunction polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement. J Am Coll Cardiol 55:2427-2434
69. Hulot JS, Bura A, Villard E et al (2006) Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 108:2244-2247
70. Hulot JS, Collet JP, Silvain J et al (2010) Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis. J Am Coll Cardiol 56:134-143
71. Husted S, Emanuelsson H, Heptinstall S et al (2006) Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J 27:1038-1047
72. Jacobsson F, Swahn E, Wallentin L et al (2002) Safety profile and tolerability of intravenous ARC69931MX, a new antiplatelet drug, in unstable angina pectoris and non-Q-wave myocardial infarction. Clin Ther 24:752-765
73. Jakubowski JA, Matsushima N, Asai F et al (2007) A multiple dose study of prasugrel (CS-747), a novel thienopyridine P2Y12 inhibitor, compared with clopidogrel in healthy humans. Br J Clin Pharmacol 63:421-430
74. Jernberg T, Payne CD, Winters KJ et al (2006) Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur Heart J 27:1166-1173
75. Juurlink DN, Gomes T, Ko DT et al (2009) A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 180:713-718
76. Kazui M, Nishiya Y, Ishizuka T et al (2010) Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos 38:92-99
77. Lange RA, Hillis LD (2004) Antiplatelet therapy for ischemic heart disease. N Engl J Med 350:277-280
78. Lau WC, Waskell LA, Watkins PB et al (2003) Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation 107:32-37
79. Lau WC, Gurbel PA, Watkins PB et al (2004) Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation 109:166-171
80. Leon MB, Baim DS, Popma JJ et al (1998) A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med 339:1665-1671
81. Leonardi S, Rao SV, Harrington RA et al (2010) Rationale and design of the randomized, doubleblind trial testing INtraveNous and Oral administration of elinogrel, a selective and reversible P2Y(12)-receptor inhibitor, versus clopidogrel to eVAluate Tolerability and Efficacy in nonurgent Percutaneous Coronary Interventions patients (INNOVATE-PCI). Am Heart J 160:65-72
82. Lewis JP, Fisch AS, Ryan K et al (2011) Paraoxonase 1 (PON1) gene variants are not associated with clopidogrel response. Clin Pharmacol Ther 90(4):568-74
83. Mahaffey KW, Wojdyla DM, Carroll K et al (2011) Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation 124:544-554
84. Marcucci R, Gori AM, Paniccia R et al (2009) Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up. Circulation 119:237-242
85. Matetzky S, Shenkman B, Guetta V et al (2004) Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 109:3171-3175
86. Mega JL, Close SL, Wiviott SD et al (2009) Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 360:354-362
87. Mega JL, Simon T, Collet JP et al (2010a) Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA 304:1821-1830
88. Mega JL, Close SL, Wiviott SD et al (2010b) Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet 376:1312-1319
89. Mehta SR, Tanguay JF, Eikelboom JW et al (2010a) Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet 376:1233-1243
90. Mehta SR, Bassand JP, Chrolavicius S et al (2010b) Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med 363:930-942
91. Migliorini A, Valenti R, Marcucci R et al (2009) High residual platelet reactivity after clopidogrel loading and long-term clinical outcome after drug-eluting stenting for unprotected left main coronary disease. Circulation 120:2214-2221
92. Mokhtar OA, Lemesle G, Armero S et al (2010) Relationship between platelet reactivity inhibition and non-CABG related major bleeding in patients undergoing percutaneous coronary intervention. Thromb Res 126:e147-e149
93. Montalescot G, Sideris G, Meuleman C et al (2006) A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial. J Am Coll Cardiol 48:931-938
94. Montalescot G, Wiviott SD, Braunwald E et al (2009) Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet 373:723-731
95. Moussa I, Oetgen M, Roubin G et al (1999) Effectiveness of clopidogrel and aspirin versus ticlopidine and aspirin in preventing stent thrombosis after coronary stent implantation. Circulation 99:2364-2366
96. Muller C, Buttner HJ, Petersen J et al (2000) A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after the placement of coronary-artery stents. Circulation 101:590-593
97. Muller I, Seyfarth M, Rudiger S et al (2001) Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement. Heart 85:92-93
98. Neubauer H, Gunesdogan B, Hanefeld C et al (2003) Lipophilic statins interfere with the inhibitory effects of clopidogrel on platelet function-a flow cytometry study. Eur Heart J 24:1744-1749
99. O'Donoghue ML, Braunwald E, Antman EM et al (2009) Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet 374:989-997
100. Oestreich JH (2010) Elinogrel, a reversible P2Y12 receptor antagonist for the treatment of acute coronary syndrome and prevention of secondary thrombotic events. Curr Opin Investig Drugs 11:340-348
101. Osmancik P, Jirmar R, Hulikova K et al (2009) A comparison of the VASP index between patients with hemodynamically complicated and uncomplicated acute myocardial infarction. Catheter Cardiovasc Interv 75:158-166
102. Pare G, Mehta SR, Yusuf S et al (2010) Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N Engl J Med 363:1704-1714
103. Patti G, Nusca A, Mangiacapra F et al (2008) Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome) study. J Am Coll Cardiol 52:1128-1133
104. Payne CD, Li YG, Small DS et al (2007) Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrel. J Cardiovasc Pharmacol 50:555-562
105. Picard-Fraire C (1983) Ticlopidine hydrochloride: relationship between dose, kinetics, plasma concentration and effect on platelet function. Thromb Res Suppl 4:119-128
106. Price MJ, Coleman JL, Steinhubl SR et al (2006) Onset and offset of platelet inhibition after highdose clopidogrel loading and standard daily therapy measured by a point-of-care assay in healthy volunteers. Am J Cardiol 98:681-684
107. Price MJ, Endemann S, Gollapudi RR et al (2008) Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J 29:992-1000
108. Price MJ, Logan DK, Walder JS et al (2011a) Recovery of platelet function following discontinuation of prasugrel or clopidogrel maintenance dosing in aspirin-treated subjects with stable coronary disease: the recovery trial. J Am Coll Cardiol 57:E1636
109. Price MJ, Berger PB, Teirstein PS et al (2011b) Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 305:1097-1105
110. Quinn MJ, Fitzgerald DJ (1999) Ticlopidine and clopidogrel. Circulation 100:1667-1672
111. Rehmel JL, Eckstein JA, Farid NA et al (2006) Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450. Drug Metab Dispos 34:600-607
112. Sarafoff N, Neumann L, Morath T et al (2011) Lack of impact of calcium-channel blockers on the pharmacodynamic effect and the clinical efficacy of clopidogrel after drug-eluting stenting. Am Heart J 161:605-610
113. Saw J, Steinhubl SR, Berger PB et al (2003) Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial. Circulation 108:921-924
114. Saw J, Brennan DM, Steinhubl SR et al (2007) Lack of evidence of a clopidogrel-statin interaction in the CHARISMA trial. J Am Coll Cardiol 50:291-295
115. Schomig A (2009) Ticagrelor-is there need for a new player in the antiplatelet-therapy field? N Engl J Med 361:1108-1111
116. Schomig A, Neumann FJ, Kastrati A et al (1996) A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 334:1084-1089
117. Serebruany VL, Midei MG, Malinin AI et al (2004) Absence of interaction between atorvastatin or other statins and clopidogrel: results from the interaction study. Arch Intern Med 164:2051-2057
118. Serebruany VL, Steinhubl SR, Berger PB et al (2005) Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 45:246-251
119. Serebruany V, Cherala G, Williams C et al (2009) Association of platelet responsiveness with clopidogrel metabolism: role of compliance in the assessment of "resistance". Am Heart J 158:925-932
120. Shuldiner AR, O'Connell JR, Bliden KP et al (2009) Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 302:849-857
121. Sibbing D, Kastrati A (2009) Risk of combining PPIs with thienopyridines: fact or fiction? Lancet 374:952-954
122. Sibbing D, von Beckerath O, Schomig A et al (2006) Diabetes mellitus and platelet function after administration of aspirin and a single 600 mg dose of clopidogrel. J Thromb Haemost 4:2566-2568
123. Sibbing D, von Beckerath O, Schomig A et al (2007) Impact of body mass index on platelet aggregation after administration of a high loading dose of 600 mg of clopidogrel before percutaneous coronary intervention. Am J Cardiol 100:203-205
124. Sibbing D, Morath T, Stegherr J et al (2009a) Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thromb Haemost 101:714-719
125. Sibbing D, Braun S, Morath T et al (2009b) Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J Am Coll Cardiol 53:849-856
126. Sibbing D, Morath T, Braun S et al (2010a) Clopidogrel response status assessed with Multiplate point-of-care analysis and the incidence and timing of stent thrombosis over six months following coronary stenting. Thromb Haemost 103:151-159
127. Sibbing D, Schulz S, Braun S et al (2010b) Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement. J Thromb Haemost 8:250-256
128. Sibbing D, von Beckerath N, Morath T et al (2010c) Oral anticoagulation with coumarin derivatives and antiplatelet effects of clopidogrel. Eur Heart J 31:1205-1211
129. Sibbing D, Gebhard D, Koch W et al (2010d) Isolated and interactive impact of common CYP2C19 genetic variants on the antiplatelet effect of chronic clopidogrel therapy. J Thromb Haemost 8:1685-1693
130. Sibbing D, Koch W, Gebhard D et al (2010e) Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation 121:512-518
131. Sibbing D, Steinhubl SR, Schulz S et al (2010f) Platelet aggregation and its association with stent thrombosis and bleeding in clopidogrel-treated patients: initial evidence of a therapeutic window. J Am Coll Cardiol 56:317-318
132. Sibbing D, Koch W, Massberg S et al (2011) No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting. Eur Heart J 32:1605-1613
133. Siller-Matula JM, Lang I, Christ G et al (2008) Calcium-channel blockers reduce the antiplatelet effect of clopidogrel. J Am Coll Cardiol 52:1557-1563
134. Siller-Matula J, Spiel A, Lang I et al (2009) Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am Heart J 157:148.e141-148.e145
135. Siller-Matula JM, Christ G, Lang IM et al (2010) Multiple electrode aggregometry predicts stent thrombosis better than the vasodilator-stimulated phosphoprotein phosphorylation assay. J Thromb Haemost 8:351-359
136. Sim SC, Risinger C, Dahl ML et al (2006) A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther 79:103-113
137. Simon T, Verstuyft C, Mary-Krause M et al (2009) Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 360:363-375
138. Smith SC Jr, Feldman TE, Hirshfeld JW Jr et al (2006) ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention). Circulation 113:e166-e286
139. Steinhubl SR (2010) Genotyping, clopidogrel metabolism, and the search for the therapeutic window of thienopyridines. Circulation 121:481-483
140. Steinhubl SR, Ellis SG, Wolski K et al (2001a) Ticlopidine pretreatment before coronary stenting is associated with sustained decrease in adverse cardiac events: data from the Evaluation of Platelet IIb/IIIa Inhibitor for Stenting (EPISTENT) Trial. Circulation 103:1403-1409
141. Steinhubl SR, Talley JD, Braden GA et al (2001b) Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter study. Circulation 103:2572-2578
142. Steinhubl SR, Berger PB, Mann JT 3rd et al (2002) Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 288:2411-2420
143. Steinhubl SR, Oh JJ, Oestreich JH et al (2008) Transitioning patients from cangrelor to clopidogrel: pharmacodynamic evidence of a competitive effect. Thromb Res 121:527-534
144. Storey RF (2011) Pharmacology and clinical trials of reversibly-binding P2Y12 inhibitors. Thromb Haemost 105(Suppl 1):S75-81
145. Storey RF, Newby LJ, Heptinstall S (2001a) Effects of P2Y(1) and P2Y(12) receptor antagonists on platelet aggregation induced by different agonists in human whole blood. Platelets 12:443-447
146. Storey RF, Oldroyd KG, Wilcox RG (2001b) Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes. Thromb Haemost 85:401-407
147. Storey RF, Angiolillo DJ, Patil SB et al (2010a) Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy. J Am Coll Cardiol 56:1456-1462
148. Storey RF, Bliden KP, Patil SB et al (2010b) Incidence of dyspnea and assessment of cardiac and pulmonary function in patients with stable coronary artery disease receiving ticagrelor, clopidogrel, or placebo in the ONSET/OFFSET study. J Am Coll Cardiol 56:185-193
149. Taubert D, von Beckerath N, Grimberg G et al (2006) Impact of P-glycoprotein on clopidogrel absorption. Clin Pharmacol Ther 80:486-501
150. Teng R, Butler K (2010) Pharmacokinetics, pharmacodynamics, tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y(12) receptor antagonist, in healthy subjects. Eur J Clin Pharmacol 66:487-496
151. Trenk D. (2011) TRIGGER-PCI: a prospective, randomized trial of prasugrel vs. clopidogrel in clopidogrel-hyporesponsive patients with stable ischemic heart disease undergoing percutaneous coronary intervention. Transcatheter Cardiovascular Therapeutics 2011, San Francisco, 9 Nov 2011
152. Trenk D, Hochholzer W, Fromm MF et al (2008) Cytochrome P450 2C19 681G > A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J Am Coll Cardiol 51:1925-1934
153. Trenk D, Hochholzer W, Fromm MF et al (2011) Paraoxonase-1 Q192R polymorphism and antiplatelet effects of clopidogrel in patients undergoing elective coronary stent placement. Circ Cardiovasc Genet 4:429-436
154. Ueno M, Rao SV, Angiolillo DJ (2010) Elinogrel: pharmacological principles, preclinical and early phase clinical testing. Future Cardiol 6:445-453
155. Ufer M, Svensson JO, Krausz KW et al (2004) Identification of cytochromes P450 2C9 and 3A4 as the major catalysts of phenprocoumon hydroxylation in vitro. Eur J Clin Pharmacol 60:173-182
156. van Giezen JJ, Nilsson L, Berntsson P et al (2009) Ticagrelor binds to human P2Y(12) independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation. J Thromb Haemost 7:1556-1565
157. van Giezen JJ, Sidaway J, Glaves P et al. (2012) Ticagrelor inhibits adenosine uptake in vitro and enhances adenosine-mediated hyperemia responses in a canine model. J Cardiovasc Pharmacol Ther
158. Varenhorst C, James S, Erlinge D et al (2009) Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirintreated patients with coronary artery disease. Eur Heart J 30:1744-1752
159. von Beckerath N, Taubert D, Pogatsa-Murray G et al (2005) Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISARCHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial. Circulation 112:2946-2950
160. Wallentin L (2009) P2Y(12) inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use. Eur Heart J 30:1964-1977
161. Wallentin L, Varenhorst C, James S et al (2008) Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. Eur Heart J 29:21-30
162. Wallentin L, Becker RC, Budaj A et al (2009) Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 361:1045-1057
163. Wallentin L, James S, Storey RF et al (2010) Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet 376:1320-1328
164. Wallentin L, Becker RC, James SK et al (2011) The PLATO trial reveals further opportunities to improve outcomes in patients with acute coronary syndrome. Editorial on Serebruany. "Viewpoint: Paradoxical excess mortality in the PLATO trial should be independently verified" (Thromb Haemost 2011; 105.5). Thromb Haemost 105:760-762
165. Wang ZJ, Zhou YJ, Liu YY et al (2009) Impact of clopidogrel resistance on thrombotic events after percutaneous coronary intervention with drug-eluting stent. Thromb Res 124:46-51
166. Wiviott SD, Antman EM, Winters KJ et al (2005) Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial. Circulation 111:3366-3373
167. Wiviott SD, Trenk D, Frelinger AL et al (2007a) Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation- Thrombolysis in Myocardial Infarction 44 trial. Circulation 116:2923-2932
168. Wiviott SD, Braunwald E, McCabe CH et al (2007b) Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357:2001-2015
169. Wiviott SD, Braunwald E, Angiolillo DJ et al (2008) Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel- Thrombolysis in Myocardial Infarction 38. Circulation 118:1626-1636
170. Wiviott SD, Antman EM, Braunwald E (2010) Prasugrel. Circulation 122:394-403
171. Wrishko RE, Ernest CS 2nd, Small DS et al (2009) Population pharmacokinetic analyses to evaluate the influence of intrinsic and extrinsic factors on exposure of prasugrel active metabolite in TRITON-TIMI 38. J Clin Pharmacol 49(8):984-98
172. Yusuf S, Zhao F, Mehta SR et al (2001) Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345:494-502